Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: A multicenter, prospective, randomized, double-blind, double-dummy clinical trial

Clinical Therapeutics

Volumn 32, Issue 11, 2010, Pages 1896-1905

  Kim, Sang Hyun ^a,b   Park, Kyungil ^a,c   Hong, Soon Joon ^d   Cho, Young Seok ^e   Sung, Ji Dong ^f   Moon, Geon Woong ^g   Yoon, Myung Ho ^h   Lee, Moo Yong ⁱ   Hyon, Min Su ^j   Kim, Dong Woon ^k   Kim, Hyo Soo ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Korea University College of Medicine   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

^f Samsung Medical Center   (South Korea)

^g The Catholic University of Korea   (South Korea)

^h Ajou University   (South Korea)

ⁱ Dong Kook University Hospital   (South Korea)

^j Soon Cheon Hyang University Hospital   (South Korea)

^k Chungbuk National University Hospital   (South Korea)

more..

Author keywords

Hydroxymethylglutaryl CoA reductase inhibitors; Hypercholesterolemia; Low density lipoprotein cholesterol

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; GENERIC DRUG; LIPILOU; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BENIGN TUMOR; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLECYSTITIS; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMMON COLD; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; ECZEMA; EPIGASTRIC PAIN; EPILEPSY; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HEADACHE; HEARING LOSS; HEMORRHOID; HEPATOBILIARY DISEASE; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIA; INDIGESTION; INSOMNIA; LACRIMAL GLAND DISEASE; LIPOMA; LOWER RESPIRATORY TRACT INFECTION; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MALE GENITAL SYSTEM DISEASE; MENTAL DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; NEUROLOGIC DISEASE; OSTEOARTHRITIS; PARESTHESIA; PATIENT COMPLIANCE; PROSPECTIVE PAYMENT; PROSTATE DISEASE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; SOMNOLENCE; SOUTH KOREA; THORAX PAIN; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; URINE INCONTINENCE; URTICARIA; VAGINA TUMOR; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUGS, GENERIC; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; KOREA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; RISK FACTORS; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649341360     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.10.004     Document Type: Article

References (19)

1. Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the Treating to New Targets study. Lancet. 2006, 368:919-928. Treating to New Targets Investigators.
2. Chhatriwalla AK, Nicholls SJ, Wang TH, et al. Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol. 2009, 53:1110-1115.
3. Delahoy PJ, Magliano DJ, Webb K, et al. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis. Clin Ther. 2009, 31:236-244.
4. Sato H, Kinjo K, Ito H, et al. Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: The OACIS-LIPID Study. Circ J. 2008, 72:17-22. Osaka Acute Coronary Insufficiency Study (OACIS)-LIPID Study Investigators.
5. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004, 110:1557-1563.
6. Johnson C, Waters DD, DeMicco DA, et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). Am J Cardiol. 2008, 102:1312-1317.
7. Shah SJ, Waters DD, Barter P, et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol. 2008, 51:1938-1943.
8. Scirica BM, Morrow DA, Cannon CP, et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2006, 47:2326-2331. PROVE IT-TIMI 22 Investigators.
9. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published correction appears in Circulation 2004;110:763]. Circulation. 2004, 110:227-239. National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, American Heart Association.
10. Tikkanen MJ, Holme I, Cater NB, et al. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus ≥65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study). Am J Cardiol. 2009, 103:577-582. Incremental DEcrease through Aggressive Lipid Lowering Investigators.
11. Arca M Atorvastatin efficacy in the prevention of cardio-vascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs. 2007, 67(Suppl 1):43-54.
12. Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008, 51:1448-1454. TNT (Treating to New Targets) Investigators.
13. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007, 357:1301-1310. Treating to New Targets Investigators.
14. International monitoring of adverse reactions to drugs: Adverse reaction terminology 1992, WHO, WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden.
15. Centers for Disease Control and Prevention, Department of Health and Human Services. Lipid Standardization Program Accessed June 28, 2010. http://www.cdc.gov/labstandards/lsp.htm.
16. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002, 347:1557-1565.
17. Ridker PM Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003, 107:363-369.
18. Ridker PM, Hennekens CH, Buring JE, Rifai N C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000, 342:836-843.
19. Kim SH, Park JS, Zo JH, et al. Treatment Gap in the Management of Hypercholesterolemia in Korea; Return on Expenditure Achieved for Lipid TherapY (REALITY). Kor Circ J. 2006, 36:593-599.